Novel heterocyclic compounds and analogues of phenolic plant natural products for kinase docking site targeting

Overview

This research program focuses on the design and study of novel heterocyclic compounds, specifically N-alkynylimidazoles, along with analogues of phenolic plant natural products. The central hypothesis is that these compounds can be engineered to selectively target the docking recognition sites on MAPKs, which are critical protein kinases involved in cellular signaling pathways. By interacting with these docking sites rather than the conventional ATP-binding site, the compounds offer a differentiated mechanism of action that may address limitations of existing kinase inhibitors, such as selectivity challenges and resistance development. The work has potential applications in drug discovery and therapeutic development for diseases where MAPK signaling plays a key role.

Technical specifications

Key research elements:

• Design and synthesis of N-alkynylimidazoles as novel heterocyclic scaffolds
• Development of analogues derived from phenolic plant natural products
• Targeting of MAPK docking recognition sites as an alternative binding strategy to traditional ATP-competitive inhibition
• Exploration of structure-activity relationships to optimize compound selectivity and binding affinity
• Application of synthetic organic chemistry and medicinal chemistry approaches

Technology readiness level

This research is at an early discovery stage, focusing on hypothesis validation and compound design. Further validation procedures and experimental studies will be needed to confirm binding interactions, assess biological activity, and advance the compounds toward preclinical development.